Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

BioMarin Pharmaceutical Inc. (BMRN)

82.97   1.61 (1.98%) 01-17 17:29
Open: 81.72 Pre. Close: 81.36
High: 83.63 Low: 81.2501
Volume: 1,306,558 Market Cap: 15,062M
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 83.703 - 84.293 84.293 - 84.751
Low: 80.153 - 80.775 80.775 - 81.258
Close: 82.154 - 83.121 83.121 - 83.872

Technical analysis

as of: 2021-01-15 4:38:16 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 100.73     One year: 108.12
Support: Support1: 76.00    Support2: 63.23
Resistance: Resistance1: 86.24    Resistance2: 92.57
Pivot: 85.75
Moving Average: MA(5): 81.73     MA(20): 86.47
MA(100): 79.04     MA(250): 91.47
MACD: MACD(12,26): 0.14     Signal(9): 1.15
Stochastic oscillator: %K(14,3): 20.33     %D(3): 15.80
RSI: RSI(14): 47.09
52-week: High: 131.95  Low: 68.25  Change(%): -5.2
Average Vol(K): 3-Month: 152097  10-Days: 201677

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
BMRN has closed above bottom band by 27.8%. Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 15 Jan 2021
BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN - Business Wire

Tue, 12 Jan 2021
Should You Buy BioMarin Pharmaceutical Inc. (BMRN) in Biotechnology Industry? - InvestorsObserver

Mon, 11 Jan 2021
What do the Fundamentals Predict for BioMarin Pharmaceutical Inc. (BMRN) Stock? - InvestorsObserver

Mon, 11 Jan 2021
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy - Yahoo Finance

Thu, 07 Jan 2021
ALXN or BMRN: Which Is the Better Value Stock Right Now? - Yahoo Finance

Mon, 04 Jan 2021
Is BioMarin Pharmaceutical (BMRN) Stock a Buy For 2021? - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 182
Shares Float (M) 180
% Held by Insiders 0.61
% Held by Institutions 100.25
Shares Short (K) 11,740
Shares Short P. Month (K) 12,060

Stock Financials

EPS 4.560
EPS Est This Year -0.740
EPS Est Next Year -0.240
Book Value (p.s.) 22.340
Profit Margin 45.74
Operating Margin -3.68
Return on Assets (ttm) -0.8
Return on Equity (ttm) 23.9
Qtrly Rev. Growth 3.4
Gross Profit (p.s.) 3.468
Sales Per Share 10.246
EBITDA (p.s.) 0.193
Qtrly Earnings Growth 1326.00
Operating Cash Flow (M) 156
Levered Free Cash Flow (M) -21

Stock Valuations

PE Ratio 18.20
PEG Ratio 1.05
Price to Book value 3.71
Price to Sales 8.10
Price to Cash Flow 96.49

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.